INmune Bio

INMB

Market cap $46.5M

INMB Hedge Fund Activity: Q1 2026 in Review

82 of the 8,134 institutional investors tracked by Wall St. Rank reported a position in INmune Bio (INMB) for Q1 2026, worth a combined $6.09M — down 23% from $7.93M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new INMB positions and 9 closed out — a net gain of 9 holders — while 25 added to existing stakes and 21 trimmed.

The largest buyer was AQR Capital Management, adding an estimated $356K. The largest seller was Dauntless Investment Group, cutting an estimated $173K.

• 82 institutional investors held INmune Bio (INMB) as of Q1 2026, up from 74 in Q4 2025.
• Funds reported $6.09M of INmune Bio stock for Q1 2026, down 23% quarter-over-quarter.
• 18 funds opened new INmune Bio positions in Q1 2026 and 9 closed out, a net change of +9 holders.
• The largest INmune Bio buyer in Q1 2026 was AQR Capital Management, an estimated $356K added.
• The largest INmune Bio seller in Q1 2026 was Dauntless Investment Group, an estimated $173K sold.

Based on aggregated 13F filings for Q1 2026.